UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sildenafil for pulmonary hypertension in neonates

Cochrane database of systematic reviews, 2007-07 (3), p.CD005494

2007

Volltextzugriff (PDF)

Targeting renal cell carcinoma with a HIF-2 antagonist

Nature (London), 2016-11, Vol.539 (7627), p.112-117

2016

Volltextzugriff (PDF)

High Antibacterial Activity and Selectivity of the Versatile Polysulfoniums that Combat Drug Resistance

Advanced materials (Weinheim), 2021-10, Vol.33 (41), p.e2104402-n/a

2021

Volltextzugriff (PDF)

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial

Clinical journal of the American Society of Nephrology, 2020-12, Vol.15 (12), p.1715-1727

2020

Volltextzugriff (PDF)

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

Nature medicine, 2015-03, Vol.21 (3), p.248-255

2015

Volltextzugriff (PDF)

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

Science translational medicine, 2017-04, Vol.9 (387)

2017

Volltextzugriff (PDF)

Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5‑Chloro‑N2‑(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)‑N4‑(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials

Journal of medicinal chemistry, 2013-07, Vol.56 (14), p.5675-5690

2013

Volltextzugriff (PDF)

Targeting the NLRP3 Inflammasome in Severe COVID-19

Frontiers in immunology, 2020-06, Vol.11, p.1518-1518

2020

Volltextzugriff (PDF)

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

Nature (London), 2016-11, Vol.539 (7627), p.107-111

2016

Volltextzugriff (PDF)

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Journal of clinical oncology, 2016-08, Vol.34 (24), p.2866-2873

2016

Volltextzugriff (PDF)

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

The New England journal of medicine, 2016-01, Vol.374 (1), p.54-61

2016

Volltextzugriff (PDF)

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement

Journal of clinical oncology, 2017-08, Vol.35 (23), p.2613-2618

2017

Volltextzugriff (PDF)

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer

Annals of oncology, 2017-04, Vol.28 (4), p.791-797

2017

Volltextzugriff (PDF)

Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents

Cochrane database of systematic reviews, 2017-08, Vol.8 (8), p.CD012537

2017

Volltextzugriff (PDF)

Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome

Journal of the American College of Cardiology, 2018-02, Vol.71 (8), p.875-886

2018

Volltextzugriff (PDF)

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1357-1367

2017

Volltextzugriff (PDF)

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis

Journal of clinical oncology, 2016-01, Vol.34 (2), p.123-129

2016

Volltextzugriff (PDF)

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Clinical cancer research, 2015-06, Vol.21 (12), p.2745-2752

2015

Volltextzugriff (PDF)

Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation

The Journal of immunology (1950), 2016-09, Vol.197 (6), p.2421-2433

2016

Volltextzugriff (PDF)

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

JAMA psychiatry (Chicago, Ill.), 2014-06, Vol.71 (6), p.637

2014

Volltextzugriff (PDF)

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

Cancer discovery, 2014-06, Vol.4 (6), p.662-673

2014

Volltextzugriff (PDF)

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Journal of medicinal chemistry, 2017-03, Vol.60 (6), p.2215-2226

2017

Volltextzugriff (PDF)

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

JAMA : the journal of the American Medical Association, 2013-03, Vol.309 (12), p.1268

2013

Volltextzugriff (PDF)

Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinson’s Disease Therapy

Journal of medicinal chemistry, 2014-02, Vol.57 (4), p.1473-1487

2014

Volltextzugriff (PDF)

1 – 25 von 5.049

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.183)
Mit Volltextzugriff
(3.199)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(4.211)
Science & Technology
(3.354)
Life Sciences & Biomedicine
(3.299)
Male
(2.998)
Sulfones - Therapeutic Use
(2.977)
Piperazines - Therapeutic Use
(2.420)
Sildenafil Citrate
(2.252)
Sulfones
(1.795)
Middle Aged
(1.596)
Female
(1.573)
Adult
(1.368)
Purines
(1.287)
Erectile Dysfunction - Drug Therapy
(1.230)
Biological And Medical Sciences
(1.209)
Medical Sciences
(1.190)
Phosphodiesterase Inhibitors - Therapeutic Use
(1.159)
Aged
(1.094)
Animals
(949)
Purines - Therapeutic Use
(937)
Treatment Outcome
(913)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(5.047)
Journals@Ovid Full Text
(2.091)
Ingenta.com
(1.932)
EZB Electronic Journals Library
(1.810)
NUS Single-Journal Subscriptions
(1.016)
IngentaConnect Journals
(919)
Access via ScienceDirect (Elsevier)
(882)
Wiley Online Library Journals
(734)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(509)
SpringerLink_现刊
(447)
Wiley Online Library
(445)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(264)
Oxford journals
(258)
Taylor & Francis
(201)
Access via Taylor & Francis
(200)
Taylor & Francis Online
(184)
Nature Journals
(168)
Nexis Uni
(111)
Access via SAGE
(111)
Oxford Journals 2020 Medicine
(109)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sildenafil for pulmonary hypertension in neonates

Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Targeting renal cell carcinoma with a HIF-2 antagonist

High Antibacterial Activity and Selectivity of the Versatile Polysulfoniums that Combat Drug Resistance

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

Targeting the NLRP3 Inflammasome in Severe COVID-19

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer

Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents

Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinson’s Disease Therapy

Suchergebnisse filtern